Shares of Pharmaceutical company Dr. Reddy's Laboratories Ltd climbed 1.7% this morning. Here are some quick facts to get you started if you are interested in the stock:
-
Dr. Reddy's Laboratories Ltd has logged a -14.6% 52 week change, compared to 16.8% for the S&P 500
-
RDY has an average analyst rating of buy and is -4.47% away from its mean target price of $15.02 per share
-
Its trailing earnings per share (EPS) is $0.79, which brings its trailing Price to Earnings (P/E) ratio to 18.2. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $0.87 and its forward P/E ratio is 16.5
-
The company has a Price to Book (P/B) ratio of 0.03 in contrast to the Health Care sector's average P/B ratio is 3.19
-
The current ratio is currently 1.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
RDY has reported YOY quarterly earnings growth of 2.0% and gross profit margins of 0.6%
-
The company's free cash flow for the last fiscal year was $545.0 Million and the average free cash flow growth rate is 8.2%
-
Dr. Reddy's Laboratories Ltd's revenues have an average growth rate of 9.2% with operating expenses growing at 9.3%. The company's current operating margins stand at 22.1%